Travoprost
Prostaglandin Analogues
Sold as IZBA · DuoTrav · Travatan · DUOTRAV PQ · TRAVATAN Z
- Drug class
- Prostaglandin Analogues
- Availability
- Prescription only
- Routes
- Ophthalmic
- Markets covered
- 4
- Products on record
- 102
- FDA reports (12 mo)
- 338
Overview
Plain-language summary, compiled from the cited regulatory records
Travoprost is a medication belonging to the prostaglandin analog drug class [1]. It is approved for reducing elevated intraocular pressure (IOP) in individuals diagnosed with open-angle glaucoma or ocular hypertension [1]. This condition involves increased pressure within the eye, which can potentially lead to vision loss if not managed [1].
Travoprost is available under various brand names, including Travatan Z [1]. In the past 12 months, there have been 338 adverse event reports associated with this active ingredient [2]. The most frequently reported issues in these reports include circumstances or information capable of leading to medication errors, eye pain, product container seal issues, the drug being ineffective, and product dose omission issues [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 88 | May 29, 2026 |
| CA Canada | Health Canada | 8 | May 21, 2025 |
| US United States | FDA | 3 | January 15, 2026 |
| EU European Union | EMA | 3 | February 5, 2026 |
GBUnited Kingdom· MHRA
88 products
Uses
1). 1).
How to take
CACanada· Health Canada
8 products
Uses
DUOTRAV® PQ (travoprost and timolol) is indicated for the reduction of elevated IOP in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers, prostaglandins, or other IOP lowering agents AND when the use of DUOTRAV PQ (the fixed combination drug) is considered appropriate.
DUOTRAV PQ should not be used to initiate therapy. 1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 2 Geriatrics Geriatics (>65 years of age): No overall differences in safety or effectiveness have been observed between elderly and other adult patients.
How to take
USUnited States· FDA
3 products
Uses
004% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Travoprost ophthalmic solution (ionic buffered solution) is a prostaglandin analog indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
( 1 )
How to take
EUEuropean Union· EMA
3 products
Uses
1).
How to take
Drug interactions
Known interactions involving Travoprost. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL044161354 · revised June 20, 2025
- [2]Health Canada (DPD) · 02278251 · revised March 22, 2025
- [3]FDA DailyMed · 00dc284f-fd96-42… · revised January 15, 2026 [PDF]
- [4]European Medicines Agency · EMEA/H/C/000665 · revised February 5, 2026
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.